TherapeuticsMD (NASDAQ:TXMD) Releases Quarterly Earnings Results, Beats Estimates By $6.13 EPS

TherapeuticsMD (NASDAQ:TXMD) released its quarterly earnings results on Tuesday. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($6.12) by $6.13, Zacks reports. TherapeuticsMD had a negative net margin of 18.83% and a negative return on equity of 2.41%.

TherapeuticsMD Trading Down 0.5%

TXMD stock traded down $0.01 during trading on Tuesday, hitting $1.95. The company had a trading volume of 14,030 shares, compared to its average volume of 59,146. The firm has a market capitalization of $22.56 million, a price-to-earnings ratio of -195.00 and a beta of 0.58. The business has a 50 day moving average of $2.14 and a 200 day moving average of $1.96. TherapeuticsMD has a fifty-two week low of $0.98 and a fifty-two week high of $2.95.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, TherapeuticsMD has a consensus rating of “Sell”.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC increased its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,273 shares of the company’s stock after purchasing an additional 19,073 shares during the quarter. Citadel Advisors LLC owned about 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.